Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

Andreas Von Knethen

Michael John Parnham

Lisa Katharina Sha

Manfred Schubert-Zsilavecz

Mario Wurglics

Daniel Flesch

Tilo Knape

Lisa Sha

Michael Parnham

The present invention pertains to a fusion polypeptide for use in treating and/or preventing organ failure in a subject suffering from sepsis, said fusion polypeptide comprises at least (i) a first portion being a Fc portion of an immunoglobulin and (ii) a second portion comprising the extracellular portion of the human B7-H1 polypeptide or a variant thereof. Moreover, also encompassed by the invention is a polynucleotide encoding said fusion polypeptide for use in treating and/or preventing organ failure in a subject suffering from sepsis.

B7-H1 fusion polypeptides for treating and preventing organ failure

The present invention pertains to a new compound E)-2-(5-((4-methoxy-2-(trifluoromethyl)quinolin-6-yl)methoxy)-2-((4-(trifluoromethyl) benzyl)oxy)-benzylidene) hexanoic acid (MTTB), and its derivatives. The compounds of the invention are useful as selective peroxisome proliferator-activated receptor gamma (PPAR&#x3b3;) antagonists and are indicated for the use in the treatment of immune related diseases such as systemic inflammation, sepsis and septic shock.

Competitive PPAR-gamma antagonists

Growing community of inventors

Nidderau, Germany

Andreas Von Knethen